CN1650981A - Compound red leaven extract medicinal preparation and its application - Google Patents
Compound red leaven extract medicinal preparation and its application Download PDFInfo
- Publication number
- CN1650981A CN1650981A CN 200410098437 CN200410098437A CN1650981A CN 1650981 A CN1650981 A CN 1650981A CN 200410098437 CN200410098437 CN 200410098437 CN 200410098437 A CN200410098437 A CN 200410098437A CN 1650981 A CN1650981 A CN 1650981A
- Authority
- CN
- China
- Prior art keywords
- monas cuspurpureus
- cuspurpureus went
- preparation
- pharmaceutical composition
- went extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
A compound medicine contains proportionally the extract of red rice, Ca-ion antagon, and medical auxiliary. Its application is also disclosed.
Description
Technical field:
The present invention relates to the compound medicament composition that two kinds of medicines are formed, said composition contains Monas cuspurpureus Went extract and calcium ion antagonist, particularly relate to containing Monas cuspurpureus Went extract 10～1000mg, calcium ion antagonist 1mg-50mg, and an amount of pharmaceutically useful adjuvant.
Background technology:
Calcium ion antagonist can be expanded peripheral arterial, can steadily reduce light, severe hypertension patient, can obviously increase FF and reduce the forearm impedance, and average systolic and diastolic pressure are reduced.
Monas cuspurpureus Went records in the Pharmacopoeia of the People's Republic of China as Chinese crude drug, " Chinese medicine voluminous dictionary ".Describe the red song of Monas cuspurpureus Went different name, be inoculated on the rice by monascus and form through fermenting process of preparing.In recent years, relevant scholar deepens continuously to the research of Monas cuspurpureus Went both at home and abroad, has found that the effective ingredient in the Monas cuspurpureus Went mainly contains: cholesterol synthetic inhibitor (lovastatin), unsaturated fatty acids, alcohols and ester type compound, multiple pigment, material for lowering blood pressure (GABA), anti-putrefaction bacteria material (MonacolinK), the Natural antioxidant: as dimemmicac5d and flavone phenol, blood sugar lowering and other biological active substanceies that waits to identify.Wherein lovastatin content is 15～20mg/g; The unsaturated fatty acid total amount reaches more than 80%.
China starts from the eighties in last century in the research to natural Antilipemic monascus, and first has released accent fat new drug---the zhibituo sheet that the Monas cuspurpureus Went that lovastatin is arranged is the single composition buchu drugmaker.Beijing University's dimension believes that having developed with the Monas cuspurpureus Went extract that contains the lovastatin chemical compound again is the medicine of main component---XUEZHIKANG JIAONANG subsequently.
These two kinds of medicine main components are the Monas cuspurpureus Went extract of lovastatin.Have some outstanding characteristics, particularly compare with simple lovastatin, contain that Monas cuspurpureus Went has stronger blood fat reducing comprehensive therapeutic effect under the identical lovastatin dosage situation, and reduced and taken stanin fat-reducing medicament for a long time and issuable toxic and side effects, its potency ratio meets the national conditions of China.
Vast amount of clinical shows that also Monas cuspurpureus Went extract has hypercholesterolemia reducing, reduces low-density lipoprotein cholesterol, reduces serum triglycerides. reduces the remarkable comprehensive therapeutic effect of atherogenic index, high density lipoprotein increasing cholesterol and takes safe. and side effect is little, and can effectively treat cardiovascular and cerebrovascular diseases such as coronary heart disease, apoplexy and the disease relevant with hyperlipidemia, and as diabetes. the nephrotic syndrome and fatty liver.Be considered to when the promising blood fat reducing material of prospect.
Monas cuspurpureus Went extract has had the Duo Jia pharmaceutical factory to produce as crude drug is domestic at present.
Monas cuspurpureus Went extract is more as the method for preparing raw material of medicine, sale is also arranged on the market, the Monas cuspurpureus Went extract that the present invention uses is that dimension letter biotechnology company of Beijing University extracts the medicine material product that forms from special Chinese medicine Monas cuspurpureus Went and rice fermentation product, and its lovastatin content is 15～20mg/g; The unsaturated fatty acid total amount is more than 80%.
At clinicing aspect, be primarily aimed at simple blood pressure lowering at present, perhaps simple blood fat reducing, curative effect is very undesirable.Therefore, at above problem, we have developed the Monas cuspurpureus Went extract compound preparation, and this medicine contains plurality of active ingredients, can cholesterol reducing, and blood pressure lowering is alleviated atherosclerosis again, has multiple efficacy of drugs, is an excellent drug prescription.
Summary of the invention:
The invention provides a kind of pharmaceutical composition, said composition contains Monas cuspurpureus Went extract and at least a antihypertensive, and both have synergism.
Pharmaceutical composition of the present invention contains Monas cuspurpureus Went extract and a kind of antihypertensive drug of effective dose.Antihypertensive drug wherein is a calcium ion antagonist.Calcium ion antagonist is selected from amlodipine, felodipine, lacidipine, nilvadipine, nifedipine, Isradipine, nitrendipine, benidipine or their pharmaceutical salts or their optical isomer.Preferred calcium ion antagonist is selected from amlodipine, felodipine, lacidipine, and preferred calcium ion antagonist is an amlodipine.
Pharmaceutical composition of the present invention is medicinal oral preparation, is selected from tablet, capsule, enteric coatel tablets, enteric coated capsule, soft capsule, slow releasing tablet, slow releasing capsule, oral cavity disintegration tablet, controlled release tablet, controlled release capsule, powder or drop pill.
Pharmaceutical composition of the present invention exists with the dosage form of unit dose, in the preparation of unit dose, contains Monas cuspurpureus Went extract 10-1000mg, contains calcium ion antagonist 1mg-50mg.Preferably contain Monas cuspurpureus Went extract 10-1000mg, contain amlodipine or its pharmaceutical salts or its optical isomer 1mg-50mg.More preferably contain Monas cuspurpureus Went extract 10-1000mg, contain amlodipine benzenesulphonate 1mg-50mg.The preparation of described unit dose refers to the per unit preparation, as every of tablet, and capsular every etc.
Pharmaceutical composition of the present invention when making preparation, can add the medicine acceptable carrier.
The present invention relates to method with calcium ion antagonist and Monas cuspurpureus Went extract treatment hypertension, angina pectoris and hyperlipidemia.With the amlodipine is example, and the amount of amlodipine and Monas cuspurpureus Went extract combination can be 2.5mg/150mg, 2.5mg/300mg, 2.5mg/450mg, 5mg/150mg, 5mg/300mg, 5mg/450mg in the side; Or be example with the lacidipine, the amount of lacidipine and Monas cuspurpureus Went extract combination can be 1mg/150mg, 1mg/300mg, 1mg/450mg, 1.5mg/150mg, 1.5mg/300mg, 1.5mg/450mg in the side.Said composition is administered twice and is used for the treatment of hypertension, angina pectoris, coronary heart disease, hypercholesterolemia, mix type hypercholesterolemia, atherosclerosis, nephrotic syndrome hyperlipemia, diabetes and merges hyperlipemia etc. every day.
The present invention relates in the pharmaceutic adjuvant, filler can be selected: microcrystalline Cellulose, lactose, mannitol, calcium carbonate, starch etc.Preferably microcrystalline cellulose and lactose.
Binding agent preferably has the polymer of high-consistency.Can select polyvidone, methylcellulose, hydroxypropyl cellulose, hypromellose, hydroxy methocel, ethyl cellulose, gelatin, guar gum and xanthan gum etc., preferred polyvidone, and hydroxypropyl cellulose.
The optional damp polyvinylpolypyrrolidone of the disintegrating agent that comprises in the compositions, cross-linking sodium carboxymethyl cellulose, carboxymethyl starch sodium, low-substituted hydroxypropyl cellulose, pre-gelatinized starch and corn starch etc., preferred polyvinylpolypyrrolidone.
The lubricant that comprises in the compositions is selected from magnesium stearate, stearic acid, Pulvis Talci, sodium lauryl sulphate and micropowder silica gel etc.
Framework material is selected from described in the compositions: hypromellose, acrylic resin II, ethyl cellulose, methylcellulose, sodium alginate, sodium carboxymethyl cellulose.
The enteric coatings material comprises: cellulose acetate phthalate ester, hydroxypropyl methyl cellulose phthalate, enteric solubility acrylic resin I, II, III number etc.
The present invention also provides preparation of drug combination method of the present invention: can adopt direct powder compression can adopt wet granulation again.Enteric coated preparation or slow releasing preparation can make at ordinary tablet or capsule outsourcing film-coat.Slow releasing preparation also can add framework material and adopt common process to make, and the preparation method of above preparation is the galenic pharmacy conventional method.
Following data declaration beneficial effect of the present invention by experiment:
Drug synergism
According to the pathological process of hypertension and hyperlipemia, we have developed the compound red leaven extract calcium ion antagonist, and both can expand peripheral arterial in conjunction with having synergism, can steadily reduce light, severe hypertension patient.Can make average systolic and diastolic pressure reduce by 10～18%.Reduce T-CHOL and LDL-C level in the serum.To the hypertriglyceridemia patient, good blood fat clarification is arranged, exogenous cholesterol absorption is reduced.Multiple composition all has fat-reducing effect in various degree, and pharmacological action is summation action, and this is the strong characteristics of this medicine effect for reducing blood fat.Get final product blood pressure lowering, again can blood fat reducing, alleviate angina pectoris, also can improve endotheliocyte, antiinflammatory, anti-immunity simultaneously, regulate platelet function and atherosclerosis.
One at random, in the clinical trial participated in of double blinding, placebo 900 people, we are example with amlodipine and Monas cuspurpureus Went extract compound preparation, illustrate that this two classes drug combination has synergism.All patients are the hypertensive patients hyperlipemia, and keep on a diet in 2 weeks before medication and inactive other fat-reducing medicaments.Be divided into 4 groups at random, independent amlodipine group (5 or 10mg), the placebo group, independent Monas cuspurpureus Went extract group (800,1000,1200mg), 6 kinds of various dose of compound amlodipine Monas cuspurpureus Went extract (5/800,5/1000,5/1200,10/800,10/1000 and 10/1200), divide every day and take for 2 times, amount to 8 weeks of medication.All patients are before taking medicine and take medicine and measure TC, TG, ALT, AST, CK and HDL respectively after 8 weeks, and look into hepatic and renal function, and in the process of the test every day periodic monitor blood pressure.Result such as following table 1,2,3:
Table 1: the compound amlodipine Monas cuspurpureus Went extract reduces the comparison of systolic pressure
| Parameter/analysis | Monas cuspurpureus Went 0mg | Monas cuspurpureus Went 800mg | Monas cuspurpureus Went 1000mg | Monas cuspurpureus Went 1200mg | |
| Ammonia chlorine 0mg | Average change value (mmHg) and placebo diversity | ????-1.8 | ????-2.1 ????-1.2 | ??-2.4 ??-2.1 | ??-3.4 ??-2.7 |
| Ammonia chlorine 5mg | Average change value (mmHg) and placebo diversity | ????-12.8 ????-9.8 | ????-16.8 ????-10.7 | ??-17.8 ??-11.2 | ??-19.5 ??-12.4 |
| Ammonia chlorine 10mg | Average change value (mmHg) and placebo diversity | ????-12.9 ????-11.6 | ????-18.2 ????-13.0 | ??-19.8 ??-13.2 | ??-21.6 ??-16.2 |
Table 2: the compound amlodipine Monas cuspurpureus Went extract reduces the comparison of diastolic pressure
| Parameter/analysis | Monas cuspurpureus Went 0mg | Monas cuspurpureus Went 800mg | Monas cuspurpureus Went 1000mg | Monas cuspurpureus Went 1200mg | |
| Ammonia chlorine 0mg | Average change value (mmHg) and placebo diversity | ????-3.3 | ????-2.3 ????-2.1 | ??-3.2 ??-2.4 | ??-3.3 ??-2.6 |
| Ammonia chlorine 5mg | Average change value (mmHg) and placebo diversity | ????-5.2 ????-4.3 | ????-6.5 ????-5.8 | ??-7.6 ??-6.0 | ??-8.9 ??-6.0 |
| Ammonia chlorine 10mg | Average change value (mmHg) and placebo diversity | ????-6.0 ????-4.8 | ????-7.2 ????-5.4 | ??-9.5 ??-7.3 | ??-9.6 ??-6.2 |
Table 3: the compound amlodipine Monas cuspurpureus Went extract reduces the comparison (%) of low-density lipoprotein cholesterol
| Parameter/analysis | Monas cuspurpureus Went 0mg | Monas cuspurpureus Went 800mg | Monas cuspurpureus Went 1000mg | Monas cuspurpureus Went 1200mg | |
| Ammonia chlorine 0mg | Average change value (%) | ????-0.5 | ????-33.0 | ??-36.5 | ??-38.9 |
| Ammonia chlorine 5mg | Average change value (%) | ????-1.0 | ????-39.6 | ??-43.8 | ??-45.0 |
| Ammonia chlorine 10mg | Average change value (%) | ????-1.9 | ????-40.6 | ??-44.2 | ??-46.8 |
By the table in as can be seen, after treating for 8 weeks, compound amlodipine Monas cuspurpureus Went extract group is with respect to independent application amlodipine and independent Monas cuspurpureus Went extract and the placebo group used, aspect reducing diastolic pressure, systolic pressure and reducing low-density lipoprotein cholesterol, compare for three groups and have statistical significance (P＜0.05), have remarkable advantages, prove that amlodipine and Monas cuspurpureus Went extract have synergism.And in the process of the test, take place without any untoward reaction.
With lacidipine and Monas cuspurpureus Went extract compound preparation is example, another at random, the clinical trial participated in of double blinding, placebo 750 people proves that this two classes drug combination has synergism.The discharge standard of case collection and to include standard in the same.Be divided into 4 groups at random, independent lacidipine group (4 or 6mg), the placebo group, independent Monas cuspurpureus Went extract group (800,1000,1200mg), 6 kinds of various dose of compound recipe lacidipine Monas cuspurpureus Went extract (4/800,4/1000,4/1200,6/800,6/1000 and 6/1200), divide every day and take for 2 times, amount to 8 weeks of medication.All patients are before taking medicine and take medicine and measure TC, TG, ALT, AST, CK and HDL respectively after 8 weeks, and look into hepatic and renal function, and in the process of the test every day periodic monitor blood pressure.Result such as following table 4,5,6:
Table 4: compound recipe lacidipine Monas cuspurpureus Went extract reduces the comparison of systolic pressure
| Parameter/analysis | Monas cuspurpureus Went 0mg | Monas cuspurpureus Went 800mg | Monas cuspurpureus Went 1000mg | Monas cuspurpureus Went 1200mg | |
| Draw western 0mg | Average change value (mmHg) and placebo diversity | ?????-1.5 | ????-2.3 ????-1.5 | ??-2.6 ??-2.2 | ??-3.0 ??-2.5 |
| Draw western 4mg | Average change value (mmHg) and placebo diversity | ?????-11.4 ?????-9.2 | ????-15.8 ????-11.6 | ??-17.6 ??-12.0 | ??-18.9 ??-13.2 |
| Draw western 6mg | Average change value (mmHg) and placebo diversity | ?????-13.0 ?????-12.4 | ????-17.9 ????-13.5 | ??-18.9 ??-14.6 | ??-19.7 ??-15.7 |
Table 5: compound recipe lacidipine Monas cuspurpureus Went extract reduces the comparison of diastolic pressure
| Parameter/analysis | Monas cuspurpureus Went 0mg | Monas cuspurpureus Went 800mg | Monas cuspurpureus Went 1000mg | Monas cuspurpureus Went 1200mg | |
| Draw western 0mg | Average change value (mmHg) and placebo diversity | ????-2.6 | ????-2.6 ????-2.2 | ??-3.0 ??-2.5 | ??-3.1 ??-2.3 |
| Draw western 4mg | Average change value (mmHg) and placebo diversity | ????-5.4 ????-4.0 | ????-6.0 ????-5.2 | ??-6.8 ??-6.1 | ??-7.8 ??-6.4 |
| Draw western 6mg | Average change value (mmHg) and placebo diversity | ????-6.2 ????-5.0 | ????-7.8 ????-5.5 | ??-8.9 ??-6.2 | ??-9.0 ??-6.1 |
Table 6: compound recipe lacidipine Monas cuspurpureus Went extract reduces the comparison (%) of low-density lipoprotein cholesterol
| Parameter/analysis | Monas cuspurpureus Went 0mg | Monas cuspurpureus Went 800mg | Monas cuspurpureus Went 1000mg | Monas cuspurpureus Went 1200mg | |
| Draw western 0mg | Average change value (%) | ????-0.6 | ????-34.5 | ??-36.8 | ??-38.4 |
| Draw western 4mg | Average change value (%) | ????-1.3 | ????-38.9 | ??-42.8 | ??-43.5 |
| Draw western 6mg | Average change value (%) | ????-1.7 | ????-41.2 | ??-43.9 | ??-45.9 |
By the table in as can be seen, after treating for 8 weeks, compound recipe lacidipine Monas cuspurpureus Went extract group is with respect to independent application lacidipine and independent Monas cuspurpureus Went extract and the placebo group used, aspect reducing diastolic pressure, systolic pressure and reducing low-density lipoprotein cholesterol, compare for three groups and have statistical significance (P＜0.05), have remarkable advantages, prove that lacidipine and Monas cuspurpureus Went extract have synergism.And in the process of the test, take place without any untoward reaction.
Pharmaceutical composition of the present invention can be used for treating hypercholesterolemia, the various constitutionales of treatment and secondary hypertension, coronary heart disease, angina pectoris, hyperlipemia complication: concurrent hyperlipemia etc. behind cerebral infarction companion hyperlipemia, acute myocardial infarction companion hyperlipemia, nephrotic syndrome and chronic renal insufficiency dialysis or the kidney transplantation treatment.
Dosage and administration: adult's usual amounts is oral: starting dose is I, II and IV, V side, reaches therapeutic effect as 2 Zhou Houwei, rises to III and VI.Once a day, tuxedo is used.Dosage can be adjusted as required, but maximal dose is no more than 910mg every day.
Prescription is formed:
Have embodiment:
Embodiment:
Embodiment 1:
Preparation amlodipine+Monas cuspurpureus Went extract ordinary tablet
| Composition | Percentage by weight % (mg/mg) | Amount/sheet (mg) |
| Amlodipine | ????0.56 | ????2.5 |
| Monas cuspurpureus Went extract | ????66.7 | ????300 |
| Lactose | ????24.3 | ????109.2 |
| Hydroxypropyl cellulose | ????3.0 | ????13.5 |
| Cross-linking sodium carboxymethyl cellulose | ????4.0 | ????18.0 |
| Micropowder silica gel | ????1.0 | ????4.5 |
| Magnesium stearate | ????0.5 | ????2.3 |
| Total amount | ????100.06 | ????450 |
Preparation method: medicine and adjuvant are crossed 80 mesh sieves respectively, and with amlodipine, Monas cuspurpureus Went extract, lactose, hydroxypropyl cellulose, coach's sodium carboxymethyl cellulose, micropowder silica gel, magnesium stearate mixing, direct powder compression promptly.
Embodiment 2:
The preparation enteric coatel tablets.
Above-mentioned ordinary tablet is done the sheet heart, enteric coated.Enteric liquid is formulated as follows:
1000
The consumption effect
Polyacrylic resin II 3.05g coating polymer
Polyacrylic resin III 3.05g coating polymer
Phthalic acid oxalic acid 1.02g plasticizer
Tween 80 0.9g emulsifying agent
Oleum Ricini 1.92g plasticizer
95% ethanol 61.1g organic solvent
Compound method: by recipe quantity take by weighing polyacrylic resin II, polyacrylic resin III places container, add 95% ethanol, under agitation, make resin moistening fully, the back sealing was stored 24 hours, make it to dissolve fully, add tween 80, diethyl phthalate, Oleum Ricini more successively, the back that stirs is standby.
Embodiment 3:
The preparation conventional capsule.
| Composition | Percentage by weight % (mg/mg) | Amount/grain (mg) |
| Levamlodipine | ????1.1 | ????5.0 |
| Monas cuspurpureus Went extract | ????66.7 | ????300.0 |
| Microcrystalline Cellulose | ????26.7 | ????120.2 |
| Polyvidone | ????1.5 | ????6.8 |
| Carboxymethyl starch sodium | ????3.0 | ????13.5 |
| Pulvis Talci | ????1.0 | ????4.5 |
| Total amount | About 100 | About 450 |
Preparation method: medicine and adjuvant are crossed 80 mesh sieves respectively, take by weighing recipe quantity Levamlodipine, Monas cuspurpureus Went extract, microcrystalline Cellulose, carboxymethyl starch sodium mixing, polyvidone 75% alcoholic solution system soft material with 5%, sieve, 60～70 ℃ of dryings, granulate is behind the adding Pulvis Talci mixing, in filling and the capsule shells.
Embodiment 4:
The preparation slow releasing capsule.
| Composition | Percentage by weight % (mg/mg) | Amount/grain (mg) |
| Lacidipine | ????0.3 | ????1.5 |
| Monas cuspurpureus Went extract | ????60.0 | ????300.0 |
| Microcrystalline Cellulose | ????12.6 | ????63.0 |
| Polyvidone | ????2.0 | ????10.0 |
| Hypromellose | ????24.1 | ????120.5 |
| Pulvis Talci | ????1.0 | ????5.0 |
| Total amount | ????100.0 | ????500 |
Preparation method: medicine and adjuvant are crossed 80 mesh sieves respectively, with lacidipine, Monas cuspurpureus Went extract, microcrystalline Cellulose, hypromellose mix homogeneously, and the polyvidone 95% alcoholic solution system soft material with 5%, sieve 60～70 ℃ of dryings, granulate, add the Pulvis Talci mixing, load in capsule shells.
Embodiment 5:
The preparation slow releasing tablet.
| Composition | Percentage by weight % (mg/mg) | Amount/sheet (mg) |
| Felodipine | ????0.6 | ????2.5 |
| Monas cuspurpureus Went extract | ????55.6 | ????250.0 |
| Hypromellose | ????25.6 | ????115.0 |
| Polyvidone | ????1.3 | ????6.0 |
| Lactose | ????15.5 | ????69.7 |
| Pulvis Talci | ????1.0 | ????4.5 |
| Magnesium stearate | ????0.5 | ????2.3 |
| Total amount | ????100.1 | ????450 |
Preparation method: medicine and adjuvant decibel are crossed 80 mesh sieves, with felodipine, Monas cuspurpureus Went extract, hydroxypropyl cellulose, lactose mixing, and the polyvidone 95% alcoholic solution system soft material with 5%, sieve 60～70 ℃ of dryings, granulate, after adding Pulvis Talci, magnesium stearate mixing, direct compression promptly.
Claims (10)
1 one kinds of pharmaceutical compositions contain the Monas cuspurpureus Went extract and at least a antihypertensive drug of effective dose.
The pharmaceutical composition of 2 claim 1, antihypertensive drug wherein is a calcium ion antagonist.
The pharmaceutical composition of 3 claim 1, wherein calcium ion antagonist is selected from amlodipine, felodipine, lacidipine, nilvadipine, nifedipine, Isradipine, nitrendipine, benidipine or their pharmaceutical salts or their optical isomer.
The pharmaceutical composition of 4 claim 1, wherein calcium ion antagonist refers to amlodipine, felodipine, lacidipine or their pharmaceutical salts or their optical isomer especially.
The pharmaceutical composition of 5 claim 1 is medicinal oral preparation, is selected from tablet, capsule, enteric coatel tablets, enteric coated capsule, soft capsule, slow releasing tablet, slow releasing capsule, oral cavity disintegration tablet, controlled release tablet, controlled release capsule, powder or drop pill.
The pharmaceutical composition of 6 claim 5 in the preparation of unit dose, contains Monas cuspurpureus Went extract 10-1000mg, contains calcium ion antagonist 1mg-50mg.
The pharmaceutical composition of 7 claim 6 in the preparation of unit dose, contains Monas cuspurpureus Went extract 10-1000mg, contains amlodipine or its pharmaceutical salts or its optical isomer 1mg-50mg.
The pharmaceutical composition of 8 claim 6 in the preparation of unit dose, contains Monas cuspurpureus Went extract 10-1000mg, contains felodipine or its pharmaceutical salts or its optical isomer 1mg-50mg.
The pharmaceutical composition of 9 claim 6 in the preparation of unit dose, contains Monas cuspurpureus Went extract 10-1000mg, contains lacidipine or its pharmaceutical salts or its optical isomer 1mg-50mg.
10 any one compositions of claim 1-9 wherein also contain the medicine acceptable carrier.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410098437 CN1650981A (en) | 2004-12-10 | 2004-12-10 | Compound red leaven extract medicinal preparation and its application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410098437 CN1650981A (en) | 2004-12-10 | 2004-12-10 | Compound red leaven extract medicinal preparation and its application |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1650981A true CN1650981A (en) | 2005-08-10 |
Family
ID=34869497
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200410098437 Pending CN1650981A (en) | 2004-12-10 | 2004-12-10 | Compound red leaven extract medicinal preparation and its application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1650981A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1919214B (en) * | 2005-08-24 | 2010-05-05 | 成都地奥九泓制药厂 | Monascus soft capsule and its preparation method |
| CN102625705A (en) * | 2009-04-08 | 2012-08-01 | 南洋理工学院 | A plant extract comprising statins and preparation techniques and uses thereof |
-
2004
- 2004-12-10 CN CN 200410098437 patent/CN1650981A/en active Pending
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1919214B (en) * | 2005-08-24 | 2010-05-05 | 成都地奥九泓制药厂 | Monascus soft capsule and its preparation method |
| CN102625705A (en) * | 2009-04-08 | 2012-08-01 | 南洋理工学院 | A plant extract comprising statins and preparation techniques and uses thereof |
| CN102625705B (en) * | 2009-04-08 | 2015-05-06 | 南洋理工学院 | A plant extract comprising statins and preparation techniques and uses thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1310643C (en) | Composition comprising a cholesterol absorption inhibitor, an HMG-CoA reductase inhibitor and a stabilizing agent | |
| CN1253497A (en) | Swallow tablet comprising paracetamol | |
| CN1939358A (en) | Sarcandra glaber dispersant tablets | |
| CN109875972B (en) | Olmesartan medoxomil and amlodipine pharmaceutical composition | |
| CN1943564A (en) | Indapamide slow release tablet and its preparing method | |
| CN1538837A (en) | Swallow tablet comprising paracetamol | |
| CN1989960A (en) | Andrographolide dispersed tablet | |
| CN1225464C (en) | Extraction technology of Hanbaicalein, medicinal composition and preparation technology of medicine | |
| CN1650981A (en) | Compound red leaven extract medicinal preparation and its application | |
| CN1698623A (en) | Dispersed composition of anti-hepatitis B virus drugs in non-crystalline form and pharmaceutical preparation thereof | |
| CN103239449A (en) | Ezetimibe, simvastatin and nicotinic acid compound preparation and preparation method of ezetimibe, simvastatin and nicotinic acid compound preparation | |
| CN101028518A (en) | Medicinal composition containing silver ester medicine and ibobulodine | |
| CN1543943A (en) | Oral silybin sustained release agent and preparation thereof | |
| CN1586493A (en) | Dioscin oral disintegration tablet and its preparing method | |
| CN1651086A (en) | Compound red yeast extract medicinal preparation and its application | |
| CN1188131C (en) | Orally taken pulsed releasing system of phenyl diazepine medicine and its prepn. | |
| CN1720941A (en) | Compound medicinal preparation with clopidogrel and red rice extracts and application thereof | |
| CN1895250A (en) | Gliquilone slow-releasing preparation | |
| CN1309376C (en) | Musk slow-controlled release preparation and preparation method thereof | |
| CN1165311C (en) | Slow-releasing composition of estrogen medicine and its preparing process | |
| CN1660432A (en) | Preparation of compound Tatin class and hepatic protectant and applications | |
| CN1679942A (en) | Compound preparation of aspirin and ginkgo biloba extract and use thereof | |
| CN1586470A (en) | Silibinin oral disintegration tablet and its preparing method | |
| CN1608623A (en) | Enteric coated donepezil hydrochloride tablet and its perpn process | |
| CN1660321A (en) | Medicinal preparation of extractive from compound aspirin and rice fermentred with red yeast |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |